Direxion Daily Financial Bull 3X Shares ETF
FAS
Direxion Daily Energy Bear 2X Shares
ERY
Ultra Financials Proshares
UYG
4
Spdr S&P Insurance Etf
KIE
5
iShares Biotechnology ETF
IBB
US Stock MarketDetailed Quotes
Zevra Therapeutics (ZVRA)
- 13.980
- +0.170+1.23%
Close Jul 2 16:00 ET
- 13.960
- -0.020-0.14%
Post 20:01 ET
826.43MMarket Cap6.96P/E (TTM)
14.040High13.525Low1.42MVolume13.850Open13.810Prev Close19.59MTurnover2.59%Turnover Ratio10.36P/E (Static)59.12MShares14.58052wk High4.02P/B767.87MFloat Cap7.16052wk Low--Dividend TTM54.93MShs Float418.400Historical High--Div Yield TTM3.73%Range %2.560Historical Low13.771Avg Price1Lot Size
ZVRA Stock Chart
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
ZVRA Orderflow
Unit: --
ZVRA Orderflow Trend
IntradayDayWeekMonth
No Data
Zevra Therapeutics (ZVRA) News
BTIG's Top Small and Mid-cap Stocks for H2, Ranked by SA Quant
BTIG Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $27
Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ), BeOne Medicines (ONC) and Zevra Therapeutics (ZVRA)
William Blair Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating
Wall Street Analysts Are Bullish on Top Healthcare Picks
Zevra Therapeutics Price Target Maintained With a $26.00/Share by HC Wainwright & Co.
Zevra Therapeutics (ZVRA) Stock Forum
$Zevra Therapeutics (ZVRA.US)$ takes time to set in , news
2
$Zevra Therapeutics (ZVRA.US)$
Analysts are recalibrating their models based on three factors that changed in the last 7 days:
Profitability Turnaround: ZVRA reported a massive Q4 EPS beat ($0.19 vs. $0.05 estimated), proving the company can generate significant cash.
Debt-Free Status: Today's $50M asset sale (SDX portfolio) allows them to clear their $63M debt, removing a major "risk overhang" that usually depresses stock prices.
Miplyffa Momentum: The drug for Niemann-Pick disease type C (N...
Analysts are recalibrating their models based on three factors that changed in the last 7 days:
Profitability Turnaround: ZVRA reported a massive Q4 EPS beat ($0.19 vs. $0.05 estimated), proving the company can generate significant cash.
Debt-Free Status: Today's $50M asset sale (SDX portfolio) allows them to clear their $63M debt, removing a major "risk overhang" that usually depresses stock prices.
Miplyffa Momentum: The drug for Niemann-Pick disease type C (N...
$Zevra Therapeutics (ZVRA.US)$ Zevra Reports Fourth Quarter and Full Year 2025 Financial Results
Q4 net revenue of $34.1 million, representing 31% growth quarter-over-quarter
FY 2025 net revenue of $106.5 million, driven by growth in MIPLYFFA® net revenue to $87.4 million
2025 EPS of $1.40 basic and $1.35 diluted
Q4 net revenue of $34.1 million, representing 31% growth quarter-over-quarter
FY 2025 net revenue of $106.5 million, driven by growth in MIPLYFFA® net revenue to $87.4 million
2025 EPS of $1.40 basic and $1.35 diluted
2
Read more
Market Insights
Hot Topics Hot Topics
Surf the ETF wave: Master the market with wisdom & ease!
As the financial landscape evolves, ETFs have emerged as a versatile tool for investors seeking to grow wealth, diversify portfolios, and st
102362254
Sep 4, 2024 16:25
Sharing my long-term ETF story
mr_cashcow
Sep 11, 2024 10:30
Low cost ETF is the way to go! September P/L challenge #6 (200words count entry)